Compare KODK & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KODK | RGNX |
|---|---|---|
| Founded | 1880 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 834.8M | 678.3M |
| IPO Year | N/A | 2015 |
| Metric | KODK | RGNX |
|---|---|---|
| Price | $8.05 | $15.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.78 |
| AVG Volume (30 Days) | ★ 1.1M | 702.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,045,000,000.00 | $161,318,000.00 |
| Revenue This Year | N/A | $132.80 |
| Revenue Next Year | N/A | $45.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $4.93 | $5.04 |
| 52 Week High | $9.96 | $15.80 |
| Indicator | KODK | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 60.86 |
| Support Level | $7.96 | $12.87 |
| Resistance Level | $8.69 | $15.80 |
| Average True Range (ATR) | 0.34 | 0.89 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 5.53 | 75.43 |
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.